Straits Times Index
3,330.09 +11.64 (+0.35%) S&P 500
5,306.04 +1.32 (+0.02%) Dow
38,852.86 -216.73 (-0.55%) Nasdaq
17,019.88 +99.09 (+0.59%) Bitcoin USD
68,540.92 -1,028.61 (-1.48%) CMC Crypto 200
1,485.03 -11.43 (-0.76%)
AMGN Jun 2024 305.000 put
| Previous close | 5.48 |
| Open | 8.36 |
| Bid | 7.90 |
| Ask | 8.30 |
| Strike | 305.00 |
| Expiry date | 2024-06-21 |
| Day's range | 8.36 - 9.19 |
| Contract range | N/A |
| Volume | |
| Open interest | 401 |
- Yahoo Finance Video
Tapping into the GLP-1 hype? Consider these pharma stocks.
Enthusiasm for GLP-1 drugs on Wall Street persists, with Eli Lilly (LLY) committing more than $5.3 billion to expand a plant involved in the production of tirzepatide weight-loss and diabetes injections. Jefferies Biotechnology Managing Director Michael Yee joins Market Domination to explain which biotech companies are hidden gems in the GLP-1 craze on Wall Street. "We have said Amgen (AMGN) is one of the most important large-cap companies that we have been very bullish on. And they, too, will go to phase three with a monthly GLP-1. And we think the data is going to be great the end of the year. There's also smaller companies, like Scholar Rock, SRRK, or Corbis that also have new modalities that are interesting," Yee tells Yahoo Finance. For more on the biotech sector and the upcoming annual conference for The American Society of Clinical Oncology, watch the full interview with Michael Yee here: https://finance.yahoo.com/video/biotech-sector-cancer-vaccines-pd-204711308.html For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Nicholas Jacobino
PR NewswireAMGEN TO PRESENT INNOVATIVE RESEARCH FROM ITS ROBUST ONCOLOGY PORTFOLIO AT ASCO 2024
Amgen (NASDAQ:AMGN) today announced the presentation of new data from its broad oncology portfolio at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, taking place from May 31-June 4 in Chicago. The 17 abstracts from Amgen-sponsored and partner-led studies, including one late-breaking oral presentation, demonstrate Amgen's commitment to innovation and meaningfully improving outcomes for people living with difficult-to-treat cancers.
ZacksBeat the Market the Zacks Way: EverQuote, Micron, Amgen in Focus
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
